Lowering of low-density lipoprotein (LDL) has been shown to reduce cardiovascular (CV) events and all-cause mortality in patients who suffer from atherosclerotic disease . Patients with polyvascular disease in particular have a significantly higher rate of major adverse cardiovascular events than patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease alone. Despite strong guideline recommendations and clinical trial data, many patients are unable to receive adequate LDL lowering therapy, which results in excess CV risk.
Peterson et al. aimed to determine the LDL treatment patterns over time in patients with polyvascular disease in the USA. In the multicentre, observational *Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management* (GOULD) Registry of atherosclerotic cardiovascular disease patients on lipid therapy, baseline treatment was assessed by medical ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Unplanned hospital readmission is common after congenital cardiac surgery Next Article
Diagnosing cardiac sarcoidosis with endomyocardial biopsies »
Table of Contents: ACC 2019
Acute and Stable Ischaemic Heart Disease
Arrhythmias and Clinical Electrophysiology
Congenital Heart Disease
Heart Failure and Cardiomyopathies
Pulmonary Arterial Hypertension and Venous Thromboembolism
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.